Tebao Biologics H1 Revenue RMB1.84 Billion, Net Profit RMB477 Million, Up 11.37%
Tebao Biologics disclosed its half-year report on August 18, 2026. In the first half of 2026, the company achieved operating revenue of RMB1.837 billion, up 21.58% year on year; net profit attributable to shareholders of the listed company was RMB477 million, up 11.37%; basic earnings per share were RMB1.17.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 40/100 and 60% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.